A 0 1 0 1 O
female 2 8 2 8 B-gender
not 9 12 9 12 O
of 13 15 13 15 O
childbearing 16 28 16 28 O
potential 29 38 29 38 O
is 39 41 39 41 O
one 42 45 42 45 O
who 46 49 46 49 O
has 50 53 50 53 O
undergone 54 63 54 63 O
bilateral 64 73 64 73 B-treatment
oophorectomies 74 88 74 88 I-treatment
or 89 91 89 91 O
who 92 95 92 95 O
is 96 98 96 98 O
postmenopausal 99 113 99 113 O
, 113 114 113 114 O
defined 115 122 115 122 O
as 123 125 123 125 O
> 126 127 126 127 O
45 127 129 127 129 B-lower_bound
years 130 135 130 135 I-lower_bound
of 136 138 136 138 O
age 139 142 139 142 B-age
and 143 146 143 146 O
without 147 154 147 154 O
a 155 156 155 156 O
menstrual 157 166 157 166 O
period 167 173 167 173 O
for 174 177 174 177 O
12 178 180 178 180 O
consecutive 181 192 181 192 O
months 193 199 193 199 O

Females 0 7 200 207 B-gender
of 8 10 208 210 O
childbearing 11 23 211 223 O
potential 24 33 224 233 O
must 34 38 234 238 B-pregnancy
have 39 43 239 243 I-pregnancy
a 44 45 244 245 I-pregnancy
negative 46 54 246 254 I-pregnancy
pregnancy 55 64 255 264 I-pregnancy
test 65 69 265 269 O
within 70 76 270 276 O
7 77 78 277 278 B-upper_bound
days 79 83 279 283 I-upper_bound
of 84 86 284 286 O
the 87 90 287 290 O
start 91 96 291 296 O
of 97 99 297 299 O
treatment 100 109 300 309 B-treatment
and 110 113 310 313 O
on 114 116 314 316 O
Day 117 120 317 320 O
1 121 122 321 322 O
before 123 129 323 329 O
the 130 133 330 333 O
first 134 139 334 339 O
dose 140 144 340 344 O
is 145 147 345 347 O
administered 148 160 348 360 O

Subject 0 7 361 368 O
can 8 11 369 372 O
move 12 16 373 377 O
around 17 23 378 384 O
on 24 26 385 387 O
their 27 32 388 393 O
own 33 36 394 397 O
, 36 37 397 398 O
has 38 41 399 402 O
an 42 44 403 405 O
Eastern 45 52 406 413 B-clinical_variable
Cooperative 53 64 414 425 I-clinical_variable
Oncology 65 73 426 434 I-clinical_variable
Group 74 79 435 440 I-clinical_variable
( 80 81 441 442 I-clinical_variable
ECOG 81 85 442 446 I-clinical_variable
) 85 86 446 447 I-clinical_variable
performance 87 98 448 459 I-clinical_variable
status 99 105 460 466 I-clinical_variable
of 106 108 467 469 O
0 109 110 470 471 B-lower_bound
or 111 113 472 474 O
1 114 115 475 476 B-upper_bound
, 115 116 476 477 O
and 117 120 478 481 O
has 121 124 482 485 O
an 125 127 486 488 O
estimated 128 137 489 498 O
life 138 142 499 503 B-clinical_variable
expectancy 143 153 504 514 I-clinical_variable
of 154 156 515 517 O
at 157 159 518 520 O
least 160 165 521 526 O
3 166 167 527 528 B-lower_bound
months 168 174 529 535 I-lower_bound

Subject 0 7 536 543 O
is 8 10 544 546 O
currently 11 20 547 556 B-pregnancy
pregnant 21 29 557 565 I-pregnancy

Subjects 0 8 566 574 O
enrolled 9 17 575 583 O
in 18 20 584 586 O
Part 21 25 587 591 O
B 26 27 592 593 O
or 28 30 594 596 O
Part 31 35 597 601 O
C 36 37 602 603 O
must 38 42 604 608 O
have 43 47 609 613 O
at 48 50 614 616 O
least 51 56 617 622 O
1 57 58 623 624 B-lower_bound
lesion 59 65 625 631 O
that 66 70 632 636 O
may 71 74 637 640 O
qualify 75 82 641 648 O
as 83 85 649 651 O
a 86 87 652 653 O
target 88 94 654 660 O
lesion 95 101 661 667 O

Subjects 0 8 668 676 O
have 9 13 677 681 O
a 14 15 682 683 O
mean 16 20 684 688 O
QT 21 23 689 691 O
interval 24 32 692 700 O
corrected 33 42 701 710 O
by 43 45 711 713 O
the 46 49 714 717 O
Fridericia 50 60 718 728 B-clinical_variable
Correction 61 71 729 739 I-clinical_variable
formula 72 79 740 747 I-clinical_variable
value 80 85 748 753 I-clinical_variable
of 86 88 754 756 O
> 89 90 757 758 O
470 90 93 758 761 B-lower_bound
msec 94 98 762 766 I-lower_bound
( 99 100 767 768 O
in 100 102 768 770 O
females 103 110 771 778 B-gender
) 110 111 778 779 O
or 112 114 780 782 O
> 115 116 783 784 O
450 116 119 784 787 B-lower_bound
msec 120 124 788 792 I-lower_bound
( 125 126 793 794 O
in 126 128 794 796 O
males 129 134 797 802 O
) 134 135 802 803 O

Subjects 0 8 804 812 O
must 9 13 813 817 O
be 14 16 818 820 O
recovered 17 26 821 830 O
from 27 31 831 835 O
the 32 35 836 839 O
effects 36 43 840 847 O
of 44 46 848 850 O
any 47 50 851 854 O
prior 51 56 855 860 B-treatment
chemotherapy 57 69 861 873 I-treatment
, 69 70 873 874 O
immunotherapy 71 84 875 888 B-treatment
, 84 85 888 889 O
other 86 91 890 895 O
prior 92 97 896 901 B-treatment
systemic 98 106 902 910 I-treatment
anticancer 107 117 911 921 I-treatment
therapy 118 125 922 929 I-treatment
, 125 126 929 930 O
radiotherapy 127 139 931 943 B-treatment
or 140 142 944 946 O
surgery 143 150 947 954 B-treatment

Subjects 0 8 955 963 O
who 9 12 964 967 O
have 13 17 968 972 O
received 18 26 973 981 O
investigational 27 42 982 997 O
agents 43 49 998 1004 O
must 50 54 1005 1009 O
wait 55 59 1010 1014 O
at 60 62 1015 1017 O
least 63 68 1018 1023 O
4 69 70 1024 1025 B-lower_bound
weeks 71 76 1026 1031 I-lower_bound

Subjects 0 8 1032 1040 O
with 9 13 1041 1045 O
active 14 20 1046 1052 B-cancer
or 21 23 1053 1055 I-cancer
symptomatic 24 35 1056 1067 I-cancer
central 36 43 1068 1075 I-cancer
nervous 44 51 1076 1083 I-cancer
system 52 58 1084 1090 I-cancer
metastases 59 69 1091 1101 I-cancer

Subjects 0 8 1102 1110 O
with 9 13 1111 1115 O
any 14 17 1116 1119 O
other 18 23 1120 1125 O
concurrent 24 34 1126 1136 O
uncontrolled 35 47 1137 1149 O
illness 48 55 1150 1157 O
, 55 56 1157 1158 O
including 57 66 1159 1168 O
mental 67 73 1169 1175 B-chronic_disease
illness 74 81 1176 1183 I-chronic_disease
or 82 84 1184 1186 O
substance 85 94 1187 1196 O
abuse 95 100 1197 1202 O
, 100 101 1202 1203 O
which 102 107 1204 1209 O
may 108 111 1210 1213 O
interfere 112 121 1214 1223 O
with 122 126 1224 1228 O
the 127 130 1229 1232 O
ability 131 138 1233 1240 O
of 139 141 1241 1243 O
the 142 145 1244 1247 O
subject 146 153 1248 1255 O
to 154 156 1256 1258 O
cooperate 157 166 1259 1268 O
and 167 170 1269 1272 O
participate 171 182 1273 1284 O
in 183 185 1285 1287 O
the 186 189 1288 1291 O
study 190 195 1292 1297 O

Subjects 0 8 1298 1306 O
with 9 13 1307 1311 O
known 14 19 1312 1317 O
hypersensitivity 20 36 1318 1334 O
to 37 39 1335 1337 O
any 40 43 1338 1341 O
components 44 54 1342 1352 O
of 55 57 1353 1355 O
ALKS 58 62 1356 1360 B-allergy_name
4230 63 67 1361 1365 I-allergy_name

Subjects 0 8 1366 1374 O
with 9 13 1375 1379 O
known 14 19 1380 1385 O
hypersensitivity 20 36 1386 1402 O
to 37 39 1403 1405 O
any 40 43 1406 1409 O
components 44 54 1410 1420 O
of 55 57 1421 1423 O
pembrolizumab 58 71 1424 1437 B-allergy_name
( 72 73 1438 1439 O
for 73 76 1439 1442 O
patients 77 85 1443 1451 O
in 86 88 1452 1454 O
combination 89 100 1455 1466 O
arm 101 104 1467 1470 O
only 105 109 1471 1475 O
) 109 110 1475 1476 O

The 0 3 1477 1480 O
subject 4 11 1481 1488 O
is 12 14 1489 1491 O
known 15 20 1492 1497 O
to 21 23 1498 1500 O
be 24 26 1501 1503 O
positive 27 35 1504 1512 O
for 36 39 1513 1516 O
human 40 45 1517 1522 B-chronic_disease
immunodeficiency 46 62 1523 1539 I-chronic_disease
virus 63 68 1540 1545 I-chronic_disease
( 69 70 1546 1547 I-chronic_disease
HIV 70 73 1547 1550 I-chronic_disease
) 73 74 1550 1551 I-chronic_disease

planning 0 8 1552 1560 B-pregnancy
to 9 11 1561 1563 I-pregnancy
become 12 18 1564 1570 I-pregnancy
pregnant 19 27 1571 1579 I-pregnancy
during 28 34 1580 1586 O
the 35 38 1587 1590 O
study 39 44 1591 1596 O

the 0 3 1597 1600 O
subject 4 11 1601 1608 O
has 12 15 1609 1612 O
a 16 17 1613 1614 O
diagnosis 18 27 1615 1624 O
of 28 30 1625 1627 O
melanoma 31 39 1628 1636 B-cancer
or 40 42 1637 1639 O
renal 43 48 1640 1645 B-cancer
cell 49 53 1646 1650 I-cancer
carcinoma 54 63 1651 1660 I-cancer

the 0 3 1661 1664 O
subject 4 11 1665 1672 O
has 12 15 1673 1676 O
histological 16 28 1677 1689 O
or 29 31 1690 1692 O
cytological 32 43 1693 1704 O
evidence 44 52 1705 1713 O
of 53 55 1714 1716 O
a 56 57 1717 1718 O
solid 58 63 1719 1724 B-cancer
tumor 64 69 1725 1730 I-cancer

